Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMSLDHG)

• Drug Name: HPP-854 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Alzheimer disease	8A20	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMSLDHG

Molecule-Related Drug Atlas

Drug(s) Targeting Beta-secretase (BACE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
(S)-FLURBIPROFEN	DMF2O4T	Myalgia	FB56.2	Preregistration	[3]
E-2609	DMTNUJ8	Alzheimer disease	8A20	Phase 3	[4]
verubecestat	DM4CGH5	Alzheimer disease	8A20	Phase 3	[2]
Lanabecestat	DMFJLB6	Alzheimer disease	8A20	Phase 3	[5]
AZD3293	DMJQHXD	Alzheimer disease	8A20	Phase 2/3	[6]
JNJ-54861911	DMGPJ5U	Alzheimer disease	8A20	Phase 2/3	[5]
R-flurbiprofen	DMFIVSR	N. A.	N. A.	Phase 2	[3]
LY2886721	DMV14LM	Alzheimer disease	8A20	Phase 2	[7]
LY3202626	DM7IFNB	Alzheimer disease	8A20	Phase 2	[5]
AZD-3839	DM72FOD	Alzheimer disease	8A20	Phase 1	[8]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Beta-secretase (BACE)	TT8JRS7	NOUNIPROTAC	Modulator	[2]

References

• [1] ClinicalTrials.gov (NCT01482013) Safety Study of HPP854 in Subjects With Mild Cognitive Impairment or a Diagnosis of Mild Alzheimer's Disease. U.S. National Institutes of Health.
• [2] BACE1 inhibitor drugs in clinical trials for Alzheimer's disease. Alzheimers Res Ther. 2014 Dec 24;6(9):89.
• [3] The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2219-23.
• [4] Targeting the beta secretase BACE1 for Alzheimer's disease therapy. Lancet Neurol. 2014 March; 13(3): 319-329.
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] AZD3293 A novel BACE1 inhibitor: safety, tolerability, and effects on plasma and CSF A-beta peptides following single- and multiple-dose administration. Neurobiology of Aging. May 20, 2008.
• [7] Lessons from a BACE1 inhibitor trial: off-site but not off base.Alzheimers Dement.2014 Oct;10(5 Suppl):S411-9.
• [8] Discovery of AZD3839, a potent and selective BACE1 inhibitor clinical candidate for the treatment of Alzheimer disease. J Biol Chem. 2012 Nov 30;287(49):41245-57.